SemBioSys' Division, Botaneco, Commissions Commercial Manufacturing Operations

    Calgary-Based Personal Care Supplier Set to Meet Anticipated Product

    CALGARY, ALBERTA, September 19 /CNW/ - With the ability to produce
commercial volumes of their revolutionary, naturally sourced personal care and
cosmetics base emulsion, Botaneco officially commissioned its commercial
manufacturing operations at its new 10,000 square foot, state-of-the-art
facility in Calgary today. The facility will serve as the central headquarters
for the eco-friendly manufacturer, housing a fully integrated, advanced site
designed for efficient production, quality control and assurance, and

    Botaneco, a business unit of Calgary-based biotechnology company
SemBioSys, will manufacture and market branded lines of high performance,
naturally derived base emulsions and delivery systems used in the development
of cosmetics, personal care and prescription topical/dermatology products.
Botaneco is leveraging SemBioSys' proprietary technology, a first-in-class,
all-in-one system for emulsification, skin barrier protection and superior
hydration and absorption of nutrient rich moisturizers and emollients as well
as enhanced performance of skincare actives.

    The advanced facility is highlighted by the Botaneco aqueous process - a
proprietary technology that harnesses protein protected emollients without the
use of traditional extraction methods that use chemicals and solvents. The
first branded product line will be unveiled to the public October 2nd during
the Society of Cosmetic Chemists show in Long Beach, California.

    Botaneco executives expect that this site will be able to meet
anticipated aggressive demand and growth expectations. Botaneco will market,
manufacture and supply the new base emulsion and delivery system product to
businesses that manufacture and market personal care and over-the-counter
dermatology products. The Botaneco line offers a more efficient, high
performance yet natural alternative to the use of petroleum, chemical or
animal derived ingredients and delivery systems traditionally used in personal
care and cosmetics emulsifiers.

    Botaneco managing director Nancy Markley, Ph.D., said the new facility
opening is a smart move in the right direction for the SemBioSys business
unit, as demand from consumers continues to push for innovations in creating
genuinely eco-friendly products that perform equal to or better than their
synthetic counterparts. "Botaneco stands for innovation, intelligence and
smart choices. We are a company that constantly strives to find new and better
ways to not only expand our offerings, but more importantly work with our
partners to help them expand theirs. This facility will enable us to meet this
growing demand with products produced to the highest standard under a rigorous
quality control program."

    "The commissioning of Botaneco's new headquarters and manufacturing
operations is a key milestone in the implementation of SemBioSys' strategy to
generate revenue in the short and intermediate term from our
non-pharmaceutical products while creating long-term value through the
commercialization of our pharmaceutical candidates, insulin and Apo AI," said
SemBioSys President and CEO, Andrew Baum. "We believe the superior hydration
and improved skincare protection offered by Botaneco products have the
potential to transform the value proposition that its customers can offer
personal care consumers."

    Botaneco and SemBioSys will be holding a ribbon cutting ceremony later in
the fall, followed by a tour of the facility for partners, VIPs and local and
national leaders.

    About Botaneco

    From development through delivery, Botaneco is a performance based,
technologically advanced botanical science organization that manufactures and
markets a branded line of products that harness the naturally occurring
benefits of protein protected seed oils. Botaneco provides performance,
innovation and choice in creating natural, renewable and versatile delivery
systems and ingredients used in the development of cosmetics, personal care
and prescription topical/dermatology products beneficial to humans and the
environment. More information can be accessed at

    About SemBioSys (TSX VENTURE:SBS)

    With headquarters in Calgary, Alberta, SemBioSys Genetics Inc. is a
biotechnology company developing protein-based pharmaceuticals for metabolic
and cardiovascular diseases. The Company's lead pharmaceutical candidates are
recombinant human insulin to serve the rapidly expanding global diabetes
market and Apo AI, a next generation cardiovascular drug. In addition to its
pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing animal and aquaculture health,
nutritional oils and human topical markets. More information is available and
can be accessed at

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.

For further information:

For further information: Botaneco Nancy Markley, Ph.D., Managing
Director Ph: 403-717-8774 Fax: 403-250-3886 Email:
Internet: or SemBioSys Genetics Inc. Mr. Andrew Baum,
President and Chief Executive Officer Phone: 403-717-8767 Fax: 403-250-3886
E-mail: Internet: or Media Contact:
Eisen Management Group Rodger Roeser, APR 859-586-4302

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890